Pharma, Digital Pharmacies & Virtual Providers Come Together to Create Blueprint For DTC Pharma Models

An increasing number of pharmaceutical companies are introducing direct-to-consumer (DTC) drug platforms, a trend that could expand access to medications but also raises questions around regulation, oversight and responsibility.

Digital Medicine Society (DiMe) is spearheading a cross-industry initiative, working alongside drugmakers, virtual care providers and digital pharmacies to develop a scalable framework for direct-to-patient pharmaceutical models as the space continues to grow.

As major drugmakers roll out platforms that allow consumers to purchase medications directly (often at discounted prices) interest among patients appears strong. A survey found that about 75% of U.S. consumers are at least somewhat – and maybe very – likely to use these services.

Eli Lilly entered the space with the launch of LillyDirect in January 2024, and momentum has continued since then. New entrants include TrumpRx, a discount drug platform introduced earlier this year, while Johnson & Johnson recently debuted an online portal for selling select medications directly to patients in the U.S. Meanwhile, virtual care providers such as Maven Clinic and others are increasingly prioritizing direct-to-patient models, as digital pharmacies and integrated prescribing platforms expand their reach.

According to Jennifer Goldsack, CEO of DiMe, the shift comes at a time when pharmaceutical companies are dealing with pricing pressures while consumer-driven healthcare continues to gain traction, creating an opportunity to scale direct-to-patient approaches in a responsible and trusted way.

Goldsack added that these models are already transforming how patients access care, particularly in areas where demand exceeds the capacity of traditional in-person healthcare systems.

The DiMe-led initiative aims to establish a standardized operational and regulatory framework grounded in evidence, ensuring that these models function safely, consistently and with public trust.

Goldsack said in an interview that pharmaceutical companies will need to find ways to ensure patients can access medications at affordable prices while still maintaining the revenue required to fund research and development. She emphasized that, alongside industry goals, DiMe is equally focused on ensuring that patients who could benefit from treatments are able to obtain them.

The initiative currently includes four major pharmaceutical participants, with plans to expand further. Founding partners span a range of healthcare and digital health organizations.

Direct cash-pay options for medications have expanded quickly, driven by barriers to access, complex pricing structures and strong demand—particularly for therapies such as GLP-1 drugs.

Goldsack noted that patients are increasingly turning to virtual care channels to obtain treatment. She added that, amid supportive policy trends, pricing pressures on drugmakers and growing patient preference for convenient, end-to-end care solutions – including home delivery of prescriptions and ongoing support – direct-to-patient pharmaceutical models are evolving beyond niche use cases. 

According to her, these models have the potential to become a mainstream care pathway that enhances access, improves patient value and supports the sustainability of pharmaceutical innovation. She added that if direct-to-patient models are expected to become a core care pathway, it is essential to ensure they are built in a way that is reliable, broadly accessible and beneficial across the healthcare ecosystem, with clearly defined roles and responsibilities for all involved.

The Rise of DTC Pharma Models

The DTC movement is gaining traction as patients demand convenience, transparency, and faster access to treatments. By combining the strengths of pharma innovation, digital pharmacies, and telehealth platforms, the DTC Pharma model delivers a seamless care experience—from diagnosis to prescription fulfillment.

Pharmaceutical companies are increasingly investing in DTC channels to improve patient adherence, enhance brand loyalty, and gather real-world data insights.

Role of Digital Pharmacies in DTC

Digital pharmacies play a critical role in enabling DTC Pharma by streamlining prescription fulfillment and home delivery. These platforms reduce friction in the patient journey, ensuring medications are accessible without traditional pharmacy visits.

In a DTC ecosystem, digital pharmacies also support automated refills, pricing transparency, and personalized medication management.